1. Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19
- Author
-
Khatib, Mohamad Y., Shaik, Karimulla S., Ahmed, Amna A., Alwraidat, Mohammad A., Mohamed, Ahmed S., Abou Kamar, Mohamad R., Sharaf Eldean, Mouhammad Z., Aldaraiseh, Bashar K., and Nashwan, Abdulqadir J.
- Subjects
tocilizumab ,Medicine (General) ,R5-920 ,COVID‐19 ,double‐barrel colostomy ,lower gastrointestinal bleeding ,Medicine ,Case Report ,cytomegalovirus colitis ,Case Reports ,General Medicine - Abstract
The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life‐threatening bleeding and mortality.
- Published
- 2020
- Full Text
- View/download PDF